Arterra Bioscience Past Earnings Performance
Past criteria checks 5/6
Arterra Bioscience has been growing earnings at an average annual rate of 5.3%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 1.5% per year. Arterra Bioscience's return on equity is 12.7%, and it has net margins of 36.9%.
Key information
5.3%
Earnings growth rate
-1.3%
EPS growth rate
| Biotechs Industry Growth | 14.8% |
| Revenue growth rate | 1.5% |
| Return on equity | 12.7% |
| Net Margin | 36.9% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Arterra Bioscience makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 4 | 1 | 2 | 0 |
| 31 Mar 24 | 3 | 1 | 2 | 0 |
| 31 Dec 23 | 3 | 1 | 2 | 0 |
| 30 Sep 23 | 3 | 1 | 2 | 0 |
| 30 Jun 23 | 5 | 1 | 2 | 0 |
| 31 Mar 23 | 5 | 1 | 1 | 0 |
| 31 Dec 22 | 4 | 1 | 1 | 0 |
| 30 Sep 22 | 4 | 1 | 1 | 0 |
| 30 Jun 22 | 5 | 1 | 1 | 0 |
| 31 Mar 22 | 5 | 1 | 1 | 0 |
| 31 Dec 21 | 5 | 1 | 1 | 0 |
| 30 Sep 21 | 5 | 1 | 1 | 0 |
| 30 Jun 21 | 4 | 1 | 1 | 0 |
| 31 Mar 21 | 4 | 1 | 1 | 0 |
| 31 Dec 20 | 4 | 1 | 1 | 0 |
| 30 Sep 20 | 4 | 1 | 1 | 0 |
| 30 Jun 20 | 4 | 1 | 1 | 0 |
| 31 Mar 20 | 4 | 1 | 1 | 0 |
| 31 Dec 19 | 4 | 1 | 1 | 0 |
| 30 Sep 19 | 3 | 1 | 1 | 0 |
| 30 Jun 19 | 3 | 1 | 1 | 0 |
| 31 Mar 19 | 3 | 1 | 1 | 0 |
| 31 Dec 18 | 2 | 1 | 1 | 0 |
| 31 Dec 17 | 2 | 1 | 1 | 0 |
Quality Earnings: ARBS has high quality earnings.
Growing Profit Margin: ARBS's current net profit margins (36.9%) are higher than last year (21.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ARBS's earnings have grown by 5.3% per year over the past 5 years.
Accelerating Growth: ARBS's earnings growth over the past year (36.7%) exceeds its 5-year average (5.3% per year).
Earnings vs Industry: ARBS earnings growth over the past year (36.7%) exceeded the Biotechs industry -18.2%.
Return on Equity
High ROE: ARBS's Return on Equity (12.7%) is considered low.